Ocular Therapeutix, Inc. OCUL

What this company does

The company leverages its ELUTYX technology in its commercial product DEXTENZA, a corticosteroid approved by the FDA for the treatment of ocular inflammation and pain following ophthalmic surgery, and in its product candidate OTX-TIC, a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Following FDA approval, the company commercially launched DEXTENZA for the treatment of post-surgical inflammation and pain in July 2019. DEXTENZA is the first and only FDA-approved intracanalicular insert delivering dexamethasone to treat post-surgical ocular inflammation and pain for up to 30 days with a single administration. As of December 31, 2025, Ocular Therapeutix had 325 full-time employees. Ocular Therapeutix was incorporated under the laws of the State of Delaware in 2006. The company's principal executive offices are located at 15 Crosby Drive, Bedford, MA 01730.

Written from the business description in OCULAR THERAPEUTIX, INC's annual report to the U.S. Securities and Exchange Commission, filed 5 February 2026. Every sentence was checked against that document before publication.